Recent Events & Catalysts

Arrowhead Pharmaceuticals (ARWR) — real, dated facts. Not a claim about what caused any single day's price move.

← Overview 📈 Rating History 💰 Earnings 📰 Recent Events 🔄 What Changed 📖 Thesis Evolution 🔍 Similar Stocks

Committee Signals

Proprietary signals generated by the Innellis AI committee — score changes, rating shifts, and analyst disagreements.

Agreement Shifttoday

ARWR analyst agreement shifted

ARWR's Committee agreement moved from 57.10% to 42.90% (-14.20pp, 1 day(s) apart).

Score Changetoday

ARWR committee score rose 1.8 points

ARWR's Committee score moved from 49.42 to 51.20 (+1.78, 1 day(s) apart).

Score Changeyesterday

ARWR committee score fell 1.1 points

ARWR's Committee score moved from 50.49 to 49.42 (-1.07, 1 day(s) apart).

Agreement Shiftyesterday

ARWR analyst agreement shifted

ARWR's Committee agreement moved from 42.90% to 57.10% (+14.20pp, 1 day(s) apart).

Score Change2d ago

ARWR committee score rose 0.1 points

ARWR's Committee score moved from 50.38 to 50.49 (+0.11, 1 day(s) apart).

Score Change4d ago

ARWR committee score fell 2.4 points

ARWR's Committee score moved from 52.74 to 50.38 (-2.36, 1 day(s) apart).

News

B. Riley Securities Maintains Buy on Arrowhead Pharma, Raises Price Target to $123

Benzinga · 2d ago

The Bull Case For Arrowhead Pharmaceuticals (ARWR) Could Change Following Dual Phase 3 RNAi Cardiometabolic Milestones

Yahoo · 2d ago

4 Health Care Stocks With Whale Alerts In Today’s Session

Benzinga · 4d ago

Arrowhead Pharmaceuticals Completes Enrollment in Global Phase 3 YOSEMITE Study of Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia

Yahoo · 5d ago

Ford To Rally Around 22%? Here Are 10 Top Analyst Forecasts For Monday

Benzinga · 5d ago

Arrowhead Pharmaceuticals Completes Patient Enrollment In Its Global Phase 3 YOSEMITE Clinical Study Of Zodasiran To Treat Homozygous Familial Hypercholesterolemia

Benzinga · 5d ago

HC Wainwright & Co. Maintains Buy on Arrowhead Pharma, Raises Price Target to $115

Benzinga · 5d ago

Is Arrowhead Pharmaceuticals Stock A Smart Buy After Its Transition To A Commercial Company?

Yahoo · 9d ago

SEC Filings (90 days)

Departure/appointment of directors or officers, Financial statements and exhibits

Filed 2026-06-16 · 46d ago

Results of operations (earnings release), Financial statements and exhibits

Filed 2026-05-07 · 86d ago · Material

Earnings

No recent earnings data available.

Latest Analyst Action

No recent analyst actions available.